Caricamento...
Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models
Using surrogate endpoints in clinical trials is desirable for drug development because the trials can be shortened and therefore more cost-effective. Validating a surrogate for the clinical endpoint is critical in this context. One of the key steps in statistical validation of a surrogate for a sing...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890300/ https://ncbi.nlm.nih.gov/pubmed/20577652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1198/sbr.2009.0070 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|